# A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

> **NCT03096080** · PHASE1 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 10 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Recessive

## Interventions

- **DRUG:** Tesevatinib

## Key facts

- **NCT ID:** NCT03096080
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-24
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096080, "A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03096080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*